NCT02632396 2023-05-09
Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission
Emory University
Phase 1/2 Unknown
Clinical Trials
13 trialsNCT04507477 2022-08-02
Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial
University Health Network, Toronto
Phase 1/2 Unknown
NCT04058470 2022-04-14
Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma
Sun Yat-sen University
Phase 1/2 Unknown
NCT02481310 2022-02-21
Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
Northwestern University
Phase 1/2 Unknown
NCT03778619 2020-07-28
MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin
GC Cell Corporation
Phase 1/2 Unknown
NCT02951728 2020-03-11
DR-CHOP
Ruijin Hospital
Phase 1/2 Unknown
NCT03456466 2018-03-07
Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Unknown
NCT02315118 2016-06-22
Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies
National University Hospital, Singapore
Phase 1/2 Unknown
NCT01983761 2013-11-18
Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation
Targazyme, Inc.
Phase 1/2 Unknown
NCT00397800 2012-08-28
Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma
Technical University of Munich
Phase 1/2 Unknown
NCT01509300 2012-01-13
HLA-haploidentical Hematopoietic Stem Cell Transplantation for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid Tumors
Asan Medical Center
Phase 1/2 Unknown
NCT00807196 2008-12-11
Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma
Maisonneuve-Rosemont Hospital
Phase 1/2 Unknown
NCT00384553 2006-10-06
Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma
University of Magdeburg
Phase 1/2 Unknown